Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in mRCC
NCT03297593Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Dec 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in metastatic renal cell carcinoma (mRCC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Overall Response Rate at 2 years. Started Dec 2017; status: completed.
02
Drugs
ipilimumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03297593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297593.